Why Rocket Lab Stock Is Rocketing Higher This Week

Rocket Lab delivered a Q1 2026 revenue record of $200.4 million, topping the $189.7 million consensus, with gross margin at 38.2% and a $2.2 billion backlog. Management guided Q2 revenue to $225 million-$240 million and gross margin of 33%-35%, while Deutsche Bank raised its price target 64% to $120 and Clear Street initiated coverage at $150. Shares hit an all-time high of $133.18 and are up 25.7% since Friday, though the stock trades at more than 108x sales versus a five-year average of 14.6x.

Analysis

The market is now pricing Rocket Lab less like a launch/space infrastructure company and more like an early-stage platform monopolist, which creates a sharp asymmetry: operational beats matter far less than the next few proof points on margin durability and backlog conversion. A premium multiple above 100x sales only survives if investors keep extrapolating a multi-year revenue CAGR with little evidence of operating deleveraging compression; any hint that gross margin has peaked on a mix shift toward lower-quality revenue would force a violent multiple reset. Deutsche Bank’s raise matters less for the target itself than for the signaling effect that institutional underwriters are willing to underwrite a higher terminal narrative.

The second-order winner is not necessarily RKLB itself but the entire public-space beta basket, which can rerate on sympathy flows even if fundamentals diverge. That said, this type of move tends to concentrate capital into the most liquid “story stock,” starving adjacent names of attention and causing relative underperformance for companies with slower order conversion or less visible backlog. Over the next 1-3 months, the key catalyst is not another earnings beat but whether management can validate that the backlog is executable without margin dilution and without increased working capital intensity.

The biggest risk is that the stock is now trading on a perfection scenario while the business still carries launch, execution, and customer-concentration risk that can surface suddenly. If growth remains strong but Q2 gross margin steps down faster than expected, the market may re-rate from a growth monopoly to a hardware contractor, which can cut valuation multiples by half even if revenue rises. In that context, the consensus appears to be underestimating how fragile high-multiple space names are to one quarter of cadence disruption or one large contract slip.

This is a better tactical short-vol than a clean directional short: the stock’s gap risk is large, but realized volatility should stay elevated as sell-side targets chase price and retail flow amplifies momentum. The best asymmetry is to fade strength rather than front-run a collapse, because the stock can remain overextended for weeks while the fundamental debate catches up. For longs, the trade works only if you buy into post-earnings digestion on a pullback and treat it as a momentum/multiple expansion trade, not a fundamentals-first allocation.

Key Decisions for Investors

• Reduce or hedge RKLB longs into strength over the next 1-2 weeks; the stock is priced for flawless execution, so use call overwrites or put spreads to protect against a 15-25% multiple compression if Q2 margins disappoint.
• Pair trade: long high-quality space primes with visible free-cash-flow leverage versus short RKLB for 1-3 months; the relative-value bet is that the market overpays for narrative and underprices execution risk.
• If initiating a tactical long, wait for a post-rally consolidation and buy only on a 10-15% pullback with a 6-8 week horizon; target a momentum continuation trade, not a valuation anchor.
• Watch for backlog conversion and gross margin trajectory as the next catalyst; if gross margin fails to hold near the low-30s range, exit quickly because the de-rating could be abrupt.
• For higher-conviction expression, use defined-risk call spreads instead of stock in order to cap downside from a single guidance reset while keeping upside exposure if the market continues to chase the story.